Check out our most popular compounded medications! Get Started
The Dehydroepiandrosterone 20 mg/Melatonin 3 mg Slow Release (MEM4) Oral Capsules are a specialized formulation designed to provide a controlled release of active ingredients for the management of specific disease states. Each capsule contains 20 mg of Dehydroepiandrosterone (DHEA), a hormone that plays a role in a range of physiological processes and has been used in the treatment of conditions such as adrenal insufficiency, depression, and systemic lupus erythematosus. Additionally, the capsules contain 3 mg of Melatonin, a hormone that helps regulate sleep-wake cycles and has been utilized in the treatment of sleep disorders, such as insomnia and jet lag.
The capsules are formulated with Methocel E4M, a controlled-release polymer that ensures the gradual release of DHEA and Melatonin over an extended period. This slow-release mechanism allows for sustained therapeutic effects, which can lead to reduced dosing frequency and improved patient compliance. The MEM4 formulation is particularly beneficial for patients requiring a consistent and prolonged delivery of these hormones to effectively manage their conditions.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Dehydroepiandrosterone (DHEA) and Melatonin are two hormones that play significant roles in various physiological processes. DHEA is an endogenous steroid hormone that serves as a precursor to androgens and estrogens, which are vital for a wide range of bodily functions. It has been implicated in improving bone density, increasing muscle mass, enhancing mood, and potentially modulating the immune system. On the other hand, Melatonin is primarily known for its ability to regulate sleep-wake cycles, but it also possesses antioxidant properties and may support immune function and brain health.
The combination of Dehydroepiandrosterone 20 mg and Melatonin 3 mg in a slow-release oral capsule formulation provides a synergistic approach to addressing issues related to hormonal imbalances, sleep disorders, and age-related conditions. The slow-release mechanism, facilitated by Methocel E4M, ensures a steady and prolonged delivery of the active ingredients, which can be particularly beneficial for maintaining stable hormone levels throughout the day and night, potentially improving sleep quality and overall well-being.
This formulation may be of interest in the management of conditions such as adrenal insufficiency, where DHEA levels are low, and in sleep disorders, where Melatonin supplementation can help regulate the circadian rhythm. Additionally, the antioxidant properties of both DHEA and Melatonin may confer benefits in neurodegenerative diseases and conditions associated with oxidative stress. The slow-release capsules are designed to minimize peak-trough fluctuations and reduce the need for multiple daily dosing, which can enhance patient adherence to therapy.
It is important for prescribers to consider the individual patient's health status, including any existing hormonal imbalances or sleep disturbances, when considering this formulation. Monitoring of hormone levels and sleep patterns may be advisable to optimize treatment outcomes. Patients should be counseled on the potential benefits and risks associated with hormone supplementation, and the importance of adhering to the prescribed dosing regimen to achieve the desired therapeutic effect.
For more detailed information on the Dehydroepiandrosterone 20 mg/Melatonin 3 mg Slow Release (MEM4) Oral Capsules, or if you have any questions regarding this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is committed to providing comprehensive support and guidance to both patients and healthcare providers.
Dehydroepiandrosterone (DHEA) and melatonin are two hormones that play various roles in the body. DHEA is a steroid hormone that serves as a precursor to sex hormones such as estrogen and testosterone, and it is involved in a wide range of biological effects, including immune response, energy level, mood, and libido. Melatonin is primarily known for its role in regulating sleep-wake cycles. The combination of DHEA and melatonin in a slow-release capsule aims to provide a sustained release of these hormones to potentially aid in conditions such as adrenal insufficiency, depression, insomnia, and certain age-related conditions.
When considering drug interactions, it is important to note that DHEA can potentially interact with medications that are metabolized by the liver. Drugs that affect the enzyme CYP3A4, such as ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice, may alter the metabolism of DHEA, leading to increased levels and potential side effects. Conversely, medications that induce CYP3A4, such as rifampin, carbamazepine, phenytoin, and St. John's Wort, may decrease the effectiveness of DHEA by increasing its metabolism.
Melatonin may interact with various medications, including anticoagulants, immunosuppressants, diabetes medications, birth control pills, and medications that depress the central nervous system, such as benzodiazepines, opioids, and alcohol. These interactions can either potentiate or diminish the effects of melatonin or the concomitant medication. For example, melatonin may increase the risk of bleeding when taken with anticoagulants like warfarin, and it may affect blood sugar levels in patients taking diabetes medications.
Additionally, both DHEA and melatonin may have additive effects when taken with other supplements or medications that have similar uses. For instance, taking DHEA with other hormones or supplements that affect hormone levels, such as testosterone or estrogen, may lead to hormonal imbalances. Similarly, taking melatonin with other sedatives or sleep aids may increase drowsiness and sedation.
Patients should be advised to inform their healthcare provider of all medications, supplements, and herbal products they are currently taking to avoid potential interactions. Prescribers should carefully consider the patient's medication profile before recommending this formulation and monitor for any adverse effects or changes in efficacy of concurrent medications. Regular follow-up and possibly adjusting doses of concomitant medications may be necessary to ensure safety and therapeutic effectiveness.
If you have any questions or require further information regarding this formulation and its potential drug interactions, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is committed to providing comprehensive support to both patients and prescribers.
The Dehydroepiandrosterone (DHEA) 20 mg/Melatonin 3 mg Slow Release (MEM4) Oral Capsules are a specialized formulation designed to provide a controlled release of the active ingredients over an extended period. This is achieved through the incorporation of Methocel E4M, a hydrophilic polymer that forms a gel matrix when it comes into contact with gastrointestinal fluids. As the capsule travels through the digestive system, water is absorbed into the Methocel E4M, causing it to swell and form a gel-like barrier. This barrier controls the rate at which the active ingredients, DHEA and Melatonin, are released into the bloodstream.
DHEA is a naturally occurring hormone that serves as a precursor to sex hormones such as estrogen and testosterone. It is believed to have a variety of potential health benefits, including immune system support, increased energy levels, improved mood, and enhanced libido. Melatonin, on the other hand, is a hormone that regulates the sleep-wake cycle. It is commonly used to treat sleep disorders, such as insomnia and jet lag. By combining these two hormones in a slow-release formulation, the MEM4 capsules aim to provide a steady supply of both DHEA and Melatonin to the body, potentially aiding in the regulation of hormonal balance and sleep patterns.
The slow-release mechanism of Methocel E4M is particularly beneficial for maintaining stable blood levels of the hormones over time, which can help in reducing the fluctuations that might occur with immediate-release formulations. This can lead to a more consistent therapeutic effect and may reduce the risk of side effects associated with peak concentrations of hormones. Additionally, the reduced dosing frequency made possible by the controlled-release formulation can improve patient compliance, as it is easier for patients to adhere to a medication regimen that requires less frequent dosing.
For patients and prescribers considering the use of this formulation, it is important to understand that the MEM4 capsules are designed to address specific health concerns related to DHEA and Melatonin deficiencies or imbalances. The slow-release formulation may be particularly suitable for individuals who require long-term hormone supplementation and those who benefit from a gradual and sustained hormone release to manage their condition effectively. As with any medication, it is essential to consult with a healthcare provider to determine if this formulation is appropriate for the individual's health needs.
If you have any questions or require further information about the Dehydroepiandrosterone 20 mg/Melatonin 3 mg Slow Release (MEM4) Oral Capsules, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide guidance and support to ensure the safe and appropriate use of this specialized medication.
The combination of Dehydroepiandrosterone (DHEA) and Melatonin in MEM4 Capsules is designed to provide the benefits of both hormones. DHEA is a hormone produced by the adrenal glands and serves as a precursor to sex hormones, while Melatonin is a hormone that regulates sleep. This combination may be used to address various conditions such as sleep disturbances, aging effects, and other hormonal imbalances, under a physician's guidance.
MEM4 Slow Release Capsules are formulated with Methocel E4M, which is a controlled-release polymer. This polymer matrix encapsulates the active ingredients—DHEA and Melatonin—and allows for a gradual release over an extended period. This results in sustained therapeutic effects, reduced dosing frequency, and potentially improved patient compliance, especially for medications that benefit from a controlled release profile.
The slow-release formulation provides several benefits including consistent blood levels of the hormones over a longer period, which may enhance the efficacy of the therapy. It also offers the convenience of fewer doses per day, which can improve adherence to the medication regimen and reduce the likelihood of missed doses.
Yes, MEM4 Capsules contain Melatonin, which is known to regulate the sleep-wake cycle. The slow-release formulation provides a steady release of Melatonin, which may help improve sleep quality, especially in individuals with disrupted circadian rhythms or difficulty maintaining sleep throughout the night.
It is typically recommended to take MEM4 Capsules in the evening or as directed by a healthcare provider, especially since Melatonin is involved in regulating sleep patterns. However, individual dosage and timing should be determined by a physician based on the specific needs and health conditions of the patient.
Individuals with allergies to Methocel E4M, DHEA, Melatonin, or any other components of the capsules should not take MEM4. Additionally, patients with certain medical conditions, those taking specific medications that could interact with the hormones, or women who are pregnant or breastfeeding should consult a healthcare provider before use.
Like all medications, MEM4 Capsules may cause side effects in some individuals. These could include, but are not limited to, changes in mood, disruptions in hormone levels, gastrointestinal discomfort, or allergic reactions. It is important to monitor for side effects and consult a healthcare provider if any adverse reactions occur.
Potential interactions can occur when taking MEM4 Capsules with other medications. It is essential to consult a healthcare provider before combining MEM4 with other drugs to avoid any unwanted interactions and ensure safe use.
MEM4 Capsules should be stored at room temperature, away from moisture, heat, and direct light to maintain their efficacy and prevent degradation. It is also important to keep the medication out of reach of children and pets.
Yes, MEM4 Slow Release Capsules contain the hormones DHEA and Melatonin in specific doses and are not available over-the-counter. A valid prescription from a licensed healthcare provider is required to obtain this medication.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
